Magnolol inhibits appetite and causes visceral fat loss through Growth/differentiation factor-15 (GDF-15) by activating transcription factor 4-CCAAT enhancer binding protein γ-mediated endoplasmic reticulum stress responses

Abstract

Magnolol, a compound extracted from Magnolia officinalis, demonstrates potential efficacy in addressing metabolic dysfunction and cardiovascular diseases. Its biological activities encompass anti-inflammatory, antioxidant, anticoagulant, and anti-diabetic effects. Growth/differentiation factor-15 (GDF-15), a member of the transforming growth factor β superfamily, is considered a potential therapeutic target for metabolic disorders. This study investigated the impact of magnolol on GDF-15 production and its underlying mechanism. The research examined the pharmacological effect of magnolol on GDF-15 expression in vitro and in vivo, and determined the involvement of endoplasmic reticulum (ER) stress signaling in this process. Luciferase reporter assays, chromatin immunoprecipitation, and in vitro DNA binding assays were employed to examine the regulation of GDF-15 by activating transcription factor 4 (ATF4), CCAAT enhancer binding protein γ (CEBPG), and CCCTC-binding factor (CTCF). The study also investigated the effect of magnolol and ATF4 on the activity of a putative enhancer located in the intron of the GDF-15 gene, as well as the influence of single nucleotide polymorphisms (SNPs) on magnolol and ATF4-induced transcription activity. Results demonstrated that magnolol triggers GDF-15 production in endothelial cells (ECs), hepatoma cell line G2 (HepG2) and hepatoma cell line 3B (Hep3B) cell lines, and primary mouse hepatocytes. The cooperative binding of ATF4 and CEBPG upstream of the GDF-15 gene or the E1944285 enhancer located in the intron led to full-power transcription of the GDF-15 gene. SNP alleles were found to impact the magnolol and ATF4-induced transcription activity of GDF-15. In high-fat diet ApoE^-/- mice, administration of magnolol induced GDF-15 production and partially suppressed appetite through GDF-15. These findings suggest that magnolol regulates GDF-15 expression through priming of promoter and enhancer activity, indicating its potential as a drug for the treatment of metabolic disorders.

Keywords

Magnolol / Growth/differentiation factor-15 / Activating transcription factor 4 / CCAAT enhancer binding protein γ / Enhancer / Metabolic disorder

References

[1] Lin Y, Li Y, Zeng Y, et al. Pharmacology, toxicity, bioavailability, and formulation of magnolol: an update. Front Pharmacol. 2021;12:632767. https://doi.org/10.3389/fphar.2021.632767.

[2] Chang H, Chang CY, Lee HJ, et al. Magnolol ameliorates pneumonectomy and monocrotaline-induced pulmonary arterial hypertension in rats through inhibition of angiotensin II and endothelin-1 expression. Phytomedicine. 2018; 51:205-213. https://doi.org/10.1016/j.phymed.2018.10.001.

[3] Kim YJ, Choi MS, Cha BY, et al. Long-term supplementation of honokiol and magnolol ameliorates body fat accumulation, insulin resistance, and adipose inflammation in high-fat fed mice. Mol Nutr Food Res. 2013; 57(11):1988-1998. https://doi.org/10.1002/mnfr.201300113.

[4] Alonso-Castro AJ, Zapata-Bustos R, Dominguez F, et al. Magnolia dealbata Zucc and its active principles honokiol and magnolol stimulate glucose uptake in murine and human adipocytes using the insulin-signaling pathway. Phytomedicine. 2011; 18(11):926-933. https://doi.org/10.1016/j.phymed.2011.02.015.

[5] Liu Z, Zhang H, Wang H, et al. Magnolol alleviates IL-1β-induced dysfunction of chondrocytes through repression of SIRT1/AMPK/PGC-1α signaling pathway. J Interferon Cytokine Res. 2020; 40(3):145-151. https://doi.org/10.1089/jir.2019.0139.

[6] Onoda T, Li W, Sasaki T, et al. Identification and evaluation of magnolol and chrysophanol as the principle protein tyrosine phosphatase-1B inhibitory compounds in a Kampo medicine, Masiningan. J Ethnopharmacol. 2016; 186:84-90. https://doi.org/10.1016/j.jep.2016.03.063.

[7] Choi SS, Cha BY, Lee YS, et al. Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells. Life Sci. 2009; 84(25-26):908-914. https://doi.org/10.1016/j.lfs.2009.04.001.

[8] Kim YS, Jung DH, Kim NH, et al. Effect of magnolol on TGF-beta1 and fibronectin expression in human retinal pigment epithelial cells under diabetic conditions. Eur J Pharmacol. 2007; 562(1-2):12-19. https://doi.org/10.1016/j.ejphar.2007.01.048.

[9] Yu J, Gao X, Zhang L, et al. Magnolol extends lifespan and improves age-related neurodegeneration in Caenorhabditis elegans via increase of stress resistance. Sci Rep. 2024; 14(1):3158. https://doi.org/10.1038/s41598-024-53374-9.

[10] Wang YD, Sun XJ, Yang WJ, et al. Magnolol exerts anticancer activity in hepatocellular carcinoma cells through regulating endoplasmic reticulum stress-mediated apoptotic signaling. Onco Targets Ther. 2018; 11:5219-5226. https://doi.org/10.2147/OTT.S168887.

[11] Wang D, Day EA, Townsend LK, et al. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol. 2021; 17(10):592-607. https://doi.org/10.1038/s41574-021-00529-7.

[12] Breit SN, Manandhar R, Zhang HP, et al. GDF15 enhances body weight and adiposity reduction in obese mice by leveraging the leptin pathway. Cell Metab. 2023; 35(8):1341-1355. https://doi.org/10.1016/j.cmet.2023.06.009.

[13] Zhang SY, Bruce K, Danaei Z, et al. Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight. Cell Metab. 2023; 35(5):875-886, e875. https://doi.org/10.1016/j.cmet.2023.03.014.

[14] Day EA, Ford RJ, Smith BK, et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab. 2019; 1(12):1202-1208. https://doi.org/10.1038/s42255-019-0146-4.

[15] Li A, Zhao F, Zhao Y, et al. ATF4-mediated GDF15 suppresses LPS-induced inflammation and MUC5AC in human nasal epithelial cells through the PI3K/Akt pathway. Life Sci. 2021;275:119356. https://doi.org/10.1016/j.lfs.2021.119356.

[16] Miyake M, Zhang J, Yasue A, et al. Integrated stress response regulates GDF15 secretion from adipocytes, preferentially suppresses appetite for a high-fat diet and improves obesity. iScience. 2021; 24(12):103448. https://doi.org/10.1016/j.isci.2021.103448.

[17] Tenta M, Eguchi J, Wada J. Roles of transmembrane protein 97 (TMEM97) in adipose tissue and skeletal muscle. Acta Med Okayama. 2022; 76(3):235-245.

[18] Kusuyama J, Komorizono A, Bandow K, et al. CXCL3 positively regulates adipogenic differentiation. J Lipid Res. 2016; 57(10):1806-1820. https://doi.org/10.1194/jlr.M067207.

[19] Woo SM, Min KJ, Kwon TK. Magnolol enhances the therapeutic effects of TRAIL through DR5 upregulation and downregulation of c-FLIP and Mcl-1 proteins in cancer cells. Molecules. 2020; 25(19):4591. https://doi.org/10.3390/molecules25194591.

[20] Banik K, Ranaware AM, Deshpande V, et al. Honokiol for cancer therapeutics: a traditional medicine that can modulate multiple oncogenic targets. Pharmacol Res. 2019; 144:192-209. https://doi.org/10.1016/j.phrs.2019.04.004.

[21] Chen JH, Kuo HC, Lee KF, et al. Magnolol protects neurons against ischemia injury via the downregulation of p38/MAPK, CHOP and nitrotyrosine. Toxicol Appl Pharmacol. 2014; 279(3):294-302. https://doi.org/10.1016/j.taap.2014.07.005.

[22] Ye H, Meng Y. Honokiol regulates endoplasmic reticulum stress by promoting the activation of the sirtuin 1-mediated protein kinase B pathway and ameliorates high glucose/high fat-induced dysfunction in human umbilical vein endothelial cells. Endocr J. 2021; 68(8):981-992. https://doi.org/10.1507/endocrj.EJ20-0747.

[23] Chen W, Wu J, Zhan S, et al. Honokiol inhibits endoplasmic reticulum stress-associated lipopolysaccharide-induced inflammation and apoptosis in bovine endometrial epithelial cells. Exp Ther Med. 2021; 22(6):1476. https://doi.org/10.3892/etm.2021.10911.

[24] Oyabu M, Takigawa K, Mizutani S, et al. FOXO1 cooperates with C/EBPδ and ATF4 to regulate skeletal muscle atrophy transcriptional program during fasting. FASEB J. 2022; 36(2):e22152. https://doi.org/10.1096/fj.202101385RR.

[25] Guo Q, Hu H, Liu X, et al. C/EBPβ mediates palmitate-induced musclin expression via the regulation of PERK/ATF4 pathways in myotubes. Am J Physiol Endocrinol Metab. 2019; 316(6):E1081-E1092. https://doi.org/10.1152/ajpendo.00478.2018.

[26] Renfro Z, White BE, Stephens KE. CCAAT enhancer binding protein γ (C/EBP-γ):an understudied transcription factor. Adv Biol Regul. 2022;84:100861. https://doi.org/10.1016/j.jbior.2022.100861.

[27] AlSudais H, Rajgara R, Saleh A, et al. C/EBPβ promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia. J Cachexia Sarcopenia Muscle. 2022; 13(1):743-757. https://doi.org/10.1002/jcsm.12909.

[28] Cooper C, Henderson A, Artandi S, et al. Ig/EBP (C/EBP γ) is a transdominant negative inhibitor of C/EBP family transcriptional activators. Nucleic Acids Res. 1995; 23(21):4371-4377. https://doi.org/10.1093/nar/23.21.4371.

[29] Lee YH, Williams SC, Baer M, et al. The ability of C/EBP beta but not C/EBP alpha to synergize with an Sp1 protein is specified by the leucine zipper and activation domain. Mol Cell Biol. 1997; 17(4):2038-2047. https://doi.org/10.1128/MCB.17.4.2038.

[30] Cohen DM, Won KJ, Nguyen N, et al. ATF4 licenses C/EBPβ activity in human mesenchymal stem cells primed for adipogenesis. Elife. 2015;4:e06821. https://doi.org/10.7554/eLife.06821.

[31] Chiang CK, Nangaku M, Tanaka T, et al.Endoplasmic reticulum stress signal impairs erythropoietin production: a role for ATF4. Am J Physiol Cell Physiol. 2013; 304(4):C342-353. https://doi.org/10.1152/ajpcell.00153.2012.

[32] Williams MS, Amaral FM, Simeoni F, et al. A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia. J Clin Invest. 2020; 130(3):1217-1232. https://doi.org/10.1172/JCI130809.

[33] Huang P, Peslak SA, Lan X, et al. The HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression. Blood. 2020; 135(24):2121-2132. https://doi.org/10.1182/blood.2020005301.

[34] Li T, Hu JF, Qiu X, et al.CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Mol Cell Biol. 2008; 28(20):6473-6482. https://doi.org/10.1128/MCB.00204-08.

[35] Ghasemi R, Struthers H, Wilson ER, et al. Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells. Leukemia. 2021; 35(2):404-416. https://doi.org/10.1038/s41375-020-0856-3.

[36] Sohn EJ, Kim CS, Kim YS, et al. Effects of magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. Life Sci. 2007; 80(5):468-475. https://doi.org/10.1016/j.lfs.2006.09.037.

[37] Li X, Liu Z, Liao J, et al. Network pharmacology approaches for research of traditional Chinese medicines. Chin J Nat Med. 2023; 21(5):323-332. https://doi.org/10.1016/S1875-5364(23)60429-7.

[38] Cheng L, Shi L, He C, et al. Mulberry leaf flavonoids activate BAT and induce browning of WAT to improve type 2 diabetes via regulating the AMPK/SIRT1/PGC-1α signaling pathway. Chin J Nat Med. 2023; 21(11):812-829. https://doi.org/10.1016/S1875-5364(23)60481-9.

[39] Nickel J, Gohlke BO, Erehman J, et al. SuperPred: update on drug classification and target prediction. Nucleic Acids Res. 2014; 42(Web Server issue):W26-31. https://doi.org/10.1093/nar/gku477.